| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-11-25 | sirukumab | giant cell arteritis | 3 | GSK (UK) | Inflammatory diseases |
| 2015-11-23 | cobimetinib in combination with Zelboraf® (vemurafenib) | previously untreated BRAF V600 mutation-positive advanced melanoma | 3 | Roche (Switzerland) Exelixis (USA - CA) | Cancer - Oncology |
| 2015-11-23 | ofatumumab (Arzerra®) | follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen | 3 | Genmab (Denmark) | Cancer - Oncology - Rare diseases |
| 2015-11-23 | BL-8040 in combination with standard of care immunosuppressive therapy | hypoplastic myelodysplastic syndrome (hMDS), aplastic anemia | 1-2 | BiolineRx (Israel) | Autoimmune diseases |
| 2015-11-23 | ASN100 | hospital associated S. aureus infections | 1 | Arsanis Biosciences (Austria) | Infectious diseases |
| 2015-11-21 | CA4P (fosbretabulin tromethamine) and bevacizumab | ovarian cancer | 2-3 | Mateon Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-11-20 | GLPG1972 | osteoarthritis | 1 | Galapagos (Belgium) Servier (France) | Rheumatic diseases - Inflammatory diseases – Bone diseases |
| 2015-11-19 | inecalcitol | chronic myeloid leukemia (CML) | preclinical | Hybrigenics (France) | Cancer - Oncology |
| 2015-11-19 | SENS-111 | inner-ear pathologies | 1b | Sensorion (France) | Otorhinolaryngology |
| 2015-11-18 | AZD2811 | advanced solid tumours | 1 | AstraZeneca (UK) Bind Therapeutics (USA - MA) | Cancer - Oncology |
| 2015-11-18 | Keytruda® (pembrolizumab) and talimogene Laherparepvec | carcinoma of the head and neck | 1b/3 | Amgen (USA - CA) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-11-18 | AGS67E | acute myeloid leukemia | 1 | Astellas Pharma (Japan) Agensys (USA - CA) | Cancer - Oncology |
| 2015-11-18 | Jetrea® (ocriplasmin) | symptomatic vitreomacular adhesion or vitreomacular traction (VMT) including macular hole | 3 | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2015-11-17 | sequencing platform | Integragen (France) Institut Gustave Roussy (France) | Cancer - Oncology - Diagnostic | ||
| 2015-11-17 | Vacc-4x | HIV infection | 2 | Bionor Pharma (Norway) | Infectious diseases |
| 2015-11-17 | bertilimumab | moderate-to-severe ulcerative colitis | 2 | Immune Pharmaceuticals (Israel - USA) | Autoimmune diseases - Inflammatory diseases |
| 2015-11-16 | Daklinza® (daclatasvir), sofosbuvir and ribavirin | genotype 3 hepatitis C (HCV) patients with advanced fibrosis or cirrhosis | 3b | BMS (USA - NY) | Infectious diseases |
| 2015-11-16 | Iluvien® | diabetic macular edema | 3 | Alimera Sciences (USA - GA) | Ophtalmological diseases |
| 2015-11-15 | ORY-1001 | relapsed or refractory acute leukemia | 1 | Oryzon Genomics (Spain) | Cancer - Oncology |
| 2015-11-14 | SPK-RPE65 | RPE65-mediated inherited retinal dystrophies | 3 | Spark Therapeutics (USA - PA) | Ophtalmological diseases - Genetic diseases - Rare diseases |
